Home › Calculator › BBIO Dividend Calculator 2026
BBIO Dividend Calculator 2026
No dividendHealthcareBridgeBio Pharma, Inc. · NASDAQ
Price: $68.56 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
Calculator settings
BBIO is not a dividend-focused stock
BBIO pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
BBIO Dividend Yield
BridgeBio Pharma, Inc. (BBIO) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BBIO pays your bills
Year your monthly dividend income covers each expense (based on current settings)
About BridgeBio Pharma, Inc. (BBIO) — Dividend Analysis 2026
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
BBIO Dividend & DRIP — Frequently Asked Questions
Does BBIO pay a dividend?
No. BridgeBio Pharma, Inc. (BBIO) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
How can I get dividend income instead of BBIO?
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
Does BBIO have a DRIP (dividend reinvestment plan)?
A DRIP reinvests dividends into new shares. BBIO has no regular dividend in our data, so there is nothing to reinvest.
Stocks similar to BBIO
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BBIO DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BBIO position with:
🌍 BBIO Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BBIO.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BBIO Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BBIO Dividend Payment Schedule
BBIO pays quarterly — 4 times per year. Ex-div: —.
📊 BBIO vs Healthcare Benchmarks
How BBIO compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BBIO sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BBIO Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-09-17 | 8,721 | $69.01 | $601.9K | ||
| Sale | 2026-09-17 | 1,279 | $69.57 | $89.0K | ||
| Sale | 2026-08-19 | 8,100 | $83.86 | $679.3K | ||
| Sale | 2026-08-19 | 1,800 | $84.69 | $152.4K | ||
| Sale | 2026-08-19 | 100 | $85.65 | $8.6K | ||
| Sale | 2026-08-18 | 1,900 | $81.15 | $154.2K | ||
| Sale | 2026-08-18 | 17,279 | $82.21 | $1.42M | ||
| Sale | 2026-08-18 | 14,602 | $82.99 | $1.21M | ||
| Sale | 2026-08-18 | 1,199 | $83.77 | $100.4K | ||
| F-InKind | 2026-08-16 | 22,781 | $79.86 | $1.82M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare BBIO with peers: BBIO vs ASND · BBIO vs BMRN · BBIO vs EXEL
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BBIO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
BridgeBio Pharma, Inc. (BBIO) is currently trading at $68.56, 27% below its 52-week high. It does not currently pay a regular dividend.
Does BBIO Pay a Dividend? BridgeBio Pharma, Inc. Dividend Status
BridgeBio Pharma, Inc. (BBIO) is a healthcare stock trading at $68.56. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
- Without a dividend, returns depend entirely on the share price.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest BBIO News
LiveProjected your BBIO DRIP returns?
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.